US EditionPublished • loading... • Updated
Rosen Law Firm Encourages MoonLake Immunotherapeutics Investors to Inquire About Securities Class Action Investigation
Rosen Law Firm probes MoonLake for allegedly misleading trial data that triggered an 89.9% stock price drop, preparing a class action for affected shareholders.
- The Rosen Law Firm is currently organizing a lawsuit on behalf of investors who experienced losses involving securities of MoonLake Immunotherapeutics and Freeport-McMoRan as of late September 2025.
- This legal action follows MoonLake's September 29, 2025 report that its VELA-2 trial failed to achieve statistical significance, and Freeport's September 24 update on a fatal mud rush incident at its Indonesia mine.
- MoonLake stock fell 89.9% on September 29, 2025, while Freeport stock dropped 16.95% on September 24, 2025, after disclosures of business and operational setbacks.
- The Rosen Law Firm, ranked among the top four firms since 2013 and securing over $438 million for investors in 2019, advises investors they may be entitled to compensation via contingency fee arrangements.
- The ongoing investigations highlight allegations that these companies issued materially misleading information to the investing public, suggesting potential recoveries for shareholders through qualified legal counsel.
Insights by Ground AI
22 Articles
22 Articles
Coverage Details
Total News Sources22
Leaning Left4Leaning Right3Center6Last UpdatedBias Distribution46% Center
Bias Distribution
- 46% of the sources are Center
46% Center
L 31%
C 46%
R 23%
Factuality
To view factuality data please Upgrade to Premium
